Story

Kenvue Misses Q2 Estimates as Inflation and Tariffs Squeeze Margins

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
Kenvue Misses Q2 Estimates as Inflation and Tariffs Squeeze Margins
Text size
Background

Kenvue Inc. (KVUE) narrowly missed Wall Street's second-quarter expectations, as persistent inflation, tariffs, and currency headwinds compressed the company's profitability. The maker of Tylenol and Neutrogena reported both top- and bottom-line results that fell just short of analyst consensus.

Key Financials

Kenvue's performance was impacted by rising costs that offset the benefits of higher prices and supply-chain efficiencies. The company is also in the process of being acquired by Kimberly-Clark in a $40 billion deal expected to close in the fourth quarter of 2026.

  • Quarterly Sales: Rose 3% year-over-year to $3.96 billion, slightly below the analyst estimate of $3.97 billion.
  • Adjusted Profit: Came in at 31 cents per share, missing the average estimate of 32 cents, according to data from LSEG.
  • Adjusted Gross Margin: Contracted to 60.2% from 60.9% a year earlier, which the company attributed to inflation, tariffs, and unfavorable currency exchange rates.

Segment Performance

Sample IUX Markets – In-articleAd

Growth was recorded across all of Kenvue's major business segments, led by its Skin Health and Beauty division.

  • Skin Health and Beauty: Sales grew 5.1% to $1.11 billion, driven by demand for hair- and face-care products like OGX and Neutrogena.
  • Essential Health: The division, which includes Listerine and Band-Aid, saw sales increase 2.3% to $1.25 billion.
  • Self Care: Sales rose 2.2% to $1.59 billion, supported by the performance of Tylenol in the U.S. and market share gains for Zyrtec and Pepcid.

Restructuring and Outlook

Looking ahead, Kenvue is implementing a restructuring program to simplify its operations and reduce costs. The company announced it anticipates incurring approximately $250 million in pre-tax charges related to this initiative in 2026. The program is designed to streamline the company's supply chain and overall cost structure.

Read next

More on Stocks
Back to latest news

LATEST